Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, a privately held biopharmaceutical company. The acquisition focuses on the integration of Enbumyst™ ...

Esperion has acquired Corstasis Therapeutics and its nasal spray Enbumyst, which was approved by the FDA six months ago.

Detailed price information for Esperion Theraptc (ESPR-Q) from The Globe and Mail including charting and trades.

Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to ...

Patients already had high NT-proBNP levels at baseline, though, raising questions about the quality of GDMT, Nancy Sweitzer ...

Fact checked by Nick Blackmer Magnesium is a mineral essential for many bodily processes, including healthy muscle and nerve ...

A secondary analysis of the SOUL trial shows significant improvement in heart failure outcomes with oral semaglutide vs placebo, consistent with the injectable formulation.

Guideline-directed medical therapy and dose titration are essential to improving outcomes in heart failure with reduced or mildly reduced ejection fraction.According to the CDC, 6.7 million U.S.

Many of us take medications to relieve pain, fight infections, or manage chronic conditions. While these therapies offer important health benefits, it's worth understanding a lesser-known ...

The Polar Loop (Gen 2) is a solid piece of hardware, but it's by no means a straightforward subscription-free alternative to Whoop. That might be the case for some existing Polar watch users craving a ...

Esperion and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with ...

Relief Cardiovascular has announced positive 90-day results from a study of its smart heart implant technology.